Bioqube Ventures is a specialist life sciences investment firm based in Europe with a global footprint. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.
Bioqube Ventures launched its independent fund “Bioqube Factory Fund I” in 2020
… a life sciences venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients. Europe is a proven pool for hidden gems ready to be transformed into international biotechs.
… a fit-for-purpose dual investment model – besides more classical investments in investment rounds, we have special attention for “Create” projects that require additional experiments prior to creating new ventures. With our in-house “factory” model we are able to translate exciting science into trailblazing companies.
… a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths. We believe in putting our expertise at work where it matters.
The Bioqube Factory Fund I is supported by InnovFin Equity with the financial backing of the European Union under Horizon 2020, the Framework Programme for Research and Innovation. InnovFin Equity investments is deployed by the European Investment Fund.
Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer
6 March, 2023
Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform
20 October, 2022